Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119


A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL, Copland M.

Leukemia. 2020 Jan 10. doi: 10.1038/s41375-019-0700-9. [Epub ahead of print]


The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.

Vetrie D, Helgason GV, Copland M.

Nat Rev Cancer. 2020 Jan 6. doi: 10.1038/s41568-019-0230-9. [Epub ahead of print] Review.


CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Clarke CJ, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M.

Leukemia. 2020 Jan 2. doi: 10.1038/s41375-019-0684-5. [Epub ahead of print]


Defining niche interactions to target chronic myeloid leukemia stem cells.

Mitchell R, Copland M.

Haematologica. 2020 Jan;105(1):2-4. doi: 10.3324/haematol.2019.234898. No abstract available.


Predictors of Care Gaps in Home Dialysis: The Home Dialysis Virtual Ward Study.

Nadeau-Fredette AC, Chan CT, Bargman JM, Copland MA, Finkle SN, Oliver MJ, Pauly RP, Perl J, Shah NA, Zimmerman DL, Tennankore KK.

Am J Nephrol. 2019;50(5):392-400. doi: 10.1159/000503439. Epub 2019 Oct 10.


De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.

Lancet Haematol. 2019 Jul;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8. Epub 2019 Jun 12.


Is There a Role for Dose Modification of TKI Therapy in CML?

Copland M.

Curr Hematol Malig Rep. 2019 Aug;14(4):337-345. doi: 10.1007/s11899-019-00524-w. Review.


Buttonhole versus Stepladder Cannulation for Home Hemodialysis: A Multicenter, Randomized, Pilot Trial.

Huang SS, MacRae J, Ross D, Imtiaz R, Hollingsworth B, Nesrallah GE, Copland MA, McFarlane PA, Chan CT, Zimmerman D.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):403-410. doi: 10.2215/CJN.08310718. Epub 2019 Jan 18.


Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient.

Yeung EK, Copland MA, Gill S.

Clin Kidney J. 2018 Dec;11(6):786-787. doi: 10.1093/ckj/sfy012. Epub 2018 Mar 12.


Technique Failure in a Multicenter Canadian Home Hemodialysis Cohort.

Pauly RP, Rosychuk RJ, Usman I, Reintjes F, Muneer M, Chan CT, Copland M, Lindsay R, MacRae J, Nesrallah G, Pierratos A, Zimmerman DL, Komenda P.

Am J Kidney Dis. 2019 Feb;73(2):230-239. doi: 10.1053/j.ajkd.2018.08.016. Epub 2018 Nov 2.


Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal.

Toofan P, Busch C, Morrison H, O'Brien S, Jørgensen H, Copland M, Wheadon H.

Cell Death Dis. 2018 Sep 11;9(9):927. doi: 10.1038/s41419-018-0905-2.


Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.

Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, Mason J, Craine S, Mead AJ.

Br J Haematol. 2018 Sep;182(6):777-788. doi: 10.1111/bjh.15542. Epub 2018 Aug 20. Review.


Exploring Stem Cell Heterogeneity in Chronic Myeloid Leukemia.

Munje C, Copland M.

Trends Cancer. 2018 Mar;4(3):167-169. doi: 10.1016/j.trecan.2017.12.001. Epub 2017 Dec 21.


Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.

Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.

Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.


Prevalence-Based Targets Underestimate Home Dialysis Program Activity and Requirements for Growth.

Bevilacqua MU, Er L, Copland MA, Singh RS, Jamal A, Dunne ÓM, Brumby C, Levin A.

Perit Dial Int. 2018 May-Jun;38(3):200-205. doi: 10.3747/pdi.2017.00171. Epub 2018 Feb 7.


Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.

Kinstrie R, Karamitros D, Goardon N, Morrison H, Hamblin M, Robinson L, Clark RE, Copland M, Vyas P.

Blood Adv. 2016 Dec 14;1(3):160-169. doi: 10.1182/bloodadvances.2016000810. eCollection 2016 Dec 27.


Implementing the EffTox dose-finding design in the Matchpoint trial.

Brock K, Billingham L, Copland M, Siddique S, Sirovica M, Yap C.

BMC Med Res Methodol. 2017 Jul 20;17(1):112. doi: 10.1186/s12874-017-0381-x.


De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M.

Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26.


Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments.

Horne GA, Copland M.

Expert Opin Drug Discov. 2017 May;12(5):465-474. doi: 10.1080/17460441.2017.1303477. Epub 2017 Mar 14. Review.


Evaluation of a 12-Month Pilot of Long-Term and Temporary Assisted Peritoneal Dialysis.

Bevilacqua MU, Turnbull L, Saunders S, Er L, Chiu H, Hill P, Singh RS, Levin A, Copland MA, Jamal A, Brumby C, Dunne O, Taylor PA.

Perit Dial Int. 2017 May-Jun;37(3):307-313. doi: 10.3747/pdi.2016.00201. Epub 2016 Dec 1.


Intensive Hemodialysis and Potential Risks With Increasing Treatment.

Kraus MA, Kansal S, Copland M, Komenda P, Weinhandl ED, Bakris GL, Chan CT, Fluck RJ, Burkart JM.

Am J Kidney Dis. 2016 Nov;68(5S1):S51-S58. doi: 10.1053/j.ajkd.2016.05.020. Review.


Intensive Hemodialysis and Health-Related Quality of Life.

Kraus MA, Fluck RJ, Weinhandl ED, Kansal S, Copland M, Komenda P, Finkelstein FO.

Am J Kidney Dis. 2016 Nov;68(5S1):S33-S42. doi: 10.1053/j.ajkd.2016.05.023. Review.


Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.

Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.

Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Review.


What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?

Lewis M, Copland M, Soverini S, Sadovnik I, Bedel A, Prost S, Italiano A, Mahon FX.

Hematol Oncol. 2017 Dec;35(4):420-423. doi: 10.1002/hon.2329. Epub 2016 Jul 19.


Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.

Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL.

Nature. 2016 Jun 16;534(7607):341-6. doi: 10.1038/nature18288. Epub 2016 Jun 8.


Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.

Irvine DA, Zhang B, Kinstrie R, Tarafdar A, Morrison H, Campbell VL, Moka HA, Ho Y, Nixon C, Manley PW, Wheadon H, Goodlad JR, Holyoake TL, Bhatia R, Copland M.

Sci Rep. 2016 May 9;6:25476. doi: 10.1038/srep25476.


Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia.

Brehme M, Koschmieder S, Montazeri M, Copland M, Oehler VG, Radich JP, Brümmendorf TH, Schuppert A.

Sci Rep. 2016 Apr 6;6:24057. doi: 10.1038/srep24057.


Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hänzelmann S, Gusmao EG, Kintsler S, Braunschweig T, Hamilton A, Helgason GV, Copland M, Schwab A, Müller-Tidow C, Li S, Holyoake TL, Brümmendorf TH, Koschmieder S.

Leukemia. 2016 Apr;30(4):823-32. doi: 10.1038/leu.2015.329. Epub 2015 Dec 1.


Novel drug therapies in myeloid leukemia.

Horne GA, Kinstrie R, Copland M.

Pharm Pat Anal. 2015;4(3):187-205. doi: 10.4155/ppa.15.3. Review.


Hedgehog signaling in cancer stem cells: a focus on hematological cancers.

Campbell V, Copland M.

Stem Cells Cloning. 2015 Jan 16;8:27-38. doi: 10.2147/SCCAA.S58613. eCollection 2015. Review.


DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.

Lund K, Cole JJ, VanderKraats ND, McBryan T, Pchelintsev NA, Clark W, Copland M, Edwards JR, Adams PD.

Genome Biol. 2014 Aug 30;15(8):406. doi: 10.1186/s13059-014-0406-2.


The role of the bone morphogenetic proteins in leukaemic stem cell persistence.

Toofan P, Irvine D, Hopcroft L, Copland M, Wheadon H.

Biochem Soc Trans. 2014 Aug;42(4):809-15. doi: 10.1042/BST20140037. Review.


The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.

Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O'Dea M, Copland M, Pierce A, Huntly BJ, Whetton AD, Holyoake TL.

Stem Cells. 2014 Sep;32(9):2324-37. doi: 10.1002/stem.1748.


Effectiveness of deep cleaning followed by hydrogen peroxide decontamination during high Clostridium difficile infection incidence.

Best EL, Parnell P, Thirkell G, Verity P, Copland M, Else P, Denton M, Hobson RP, Wilcox MH.

J Hosp Infect. 2014 May;87(1):25-33. doi: 10.1016/j.jhin.2014.02.005. Epub 2014 Mar 12.


A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.

Braig M, Pällmann N, Preukschas M, Steinemann D, Hofmann W, Gompf A, Streichert T, Braunschweig T, Copland M, Rudolph KL, Bokemeyer C, Koschmieder S, Schuppert A, Balabanov S, Brümmendorf TH.

Leukemia. 2014 Oct;28(10):2028-39. doi: 10.1038/leu.2014.95. Epub 2014 Mar 7.


Progress in dialysis practice: an introduction.

MacRae JM, Copland M, Kiaii M.

Semin Dial. 2014 Mar;27(2):85-6. doi: 10.1111/sdi.12202. No abstract available.


In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors.

Burt C, Parker A, McQuaker G, Copland M, Brierley C, Little AM, Clark A.

Bone Marrow Transplant. 2014 May;49(5):657-63. doi: 10.1038/bmt.2014.8. Epub 2014 Feb 17.


Rationale for a home dialysis virtual ward: design and implementation.

Schachter ME, Bargman JM, Copland M, Hladunewich M, Tennankore KK, Levin A, Oliver M, Pauly RP, Perl J, Zimmerman D, Chan CT.

BMC Nephrol. 2014 Feb 14;15:33. doi: 10.1186/1471-2369-15-33.


Programmatic variation in home hemodialysis in Canada: results from a nationwide survey of practice patterns.

Pauly RP, Komenda P, Chan CT, Copland M, Gangji A, Hirsch D, Lindsay R, MacKinnon M, MacRae JM, McFarlane P, Nesrallah G, Pierratos A, Plaisance M, Reintjes F, Rioux JP, Shik J, Steele A, Stryker R, Wu G, Zimmerman DL.

Can J Kidney Health Dis. 2014 Jun 10;1:11. doi: 10.1186/2054-3581-1-11. eCollection 2014.


Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience.

Latif AL, McQuaker G, Parker A, Clark A, Copland M.

Leuk Res Rep. 2013 Jul 3;2(2):47-50. doi: 10.1016/j.lrr.2013.05.001. eCollection 2013.


EZH2 in normal and malignant hematopoiesis.

Lund K, Adams PD, Copland M.

Leukemia. 2014 Jan;28(1):44-9. doi: 10.1038/leu.2013.288. Epub 2013 Oct 7. Review.


Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.

Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG, Holyoake TL.

Blood. 2013 Nov 7;122(19):3335-9. doi: 10.1182/blood-2013-02-485607. Epub 2013 Sep 16.


Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.


Vascular access for intensive maintenance hemodialysis: a systematic review for a Canadian Society of Nephrology clinical practice guideline.

Mustafa RA, Zimmerman D, Rioux JP, Suri RS, Gangji A, Steele A, MacRae J, Pauly RP, Perkins DN, Chan CT, Copland M, Komenda P, McFarlane PA, Lindsay R, Pierratos A, Nesrallah GE.

Am J Kidney Dis. 2013 Jul;62(1):112-31. doi: 10.1053/j.ajkd.2013.03.028. Review.


Targeting self-renewal pathways in myeloid malignancies.

Sands WA, Copland M, Wheadon H.

Cell Commun Signal. 2013 May 15;11(1):33. doi: 10.1186/1478-811X-11-33.


Dialysate calcium concentration and mineral metabolism in long and long-frequent hemodialysis: a systematic review and meta-analysis for a Canadian Society of Nephrology clinical practice guideline.

Zimmerman DL, Nesrallah GE, Chan CT, Copland M, Komenda P, McFarlane PA, Gangji A, Lindsay R, MacRae J, Pauly RP, Perkins DN, Pierratos A, Rioux JP, Steele A, Suri RS, Mustafa RA.

Am J Kidney Dis. 2013 Jul;62(1):97-111. doi: 10.1053/j.ajkd.2013.02.357. Epub 2013 Apr 13. Review.


Canadian Society of Nephrology guidelines for the management of patients with ESRD treated with intensive hemodialysis.

Nesrallah GE, Mustafa RA, MacRae J, Pauly RP, Perkins DN, Gangji A, Rioux JP, Steele A, Suri RS, Chan CT, Copland M, Komenda P, McFarlane PA, Pierratos A, Lindsay R, Zimmerman DL.

Am J Kidney Dis. 2013 Jul;62(1):187-98. doi: 10.1053/j.ajkd.2013.02.351. Epub 2013 Apr 6. Review.


Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications.

Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C.

Cancer Res. 2013 Feb 1;73(3):1037-45. doi: 10.1158/0008-5472.CAN-12-3678. Epub 2013 Jan 23. Review.


Targeting chronic myeloid leukemia stem cells.

Kinstrie R, Copland M.

Curr Hematol Malig Rep. 2013 Mar;8(1):14-21. doi: 10.1007/s11899-012-0148-8. Review.


Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.

Balabanov S, Evans CA, Abraham SA, Pellicano F, Copland M, Walker MJ, Whetton AD, Holyoake TL.

Proteomics. 2013 Jan;13(1):153-68. doi: 10.1002/pmic.201200022.


Supplemental Content

Loading ...
Support Center